News
09-02-2010, 04:14 AM
The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate....
More... (http://mnt.to/f/3Jbb)
More... (http://mnt.to/f/3Jbb)